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Summary The characterisation of a new murine B cell lymphoma, A31, is described. Histopathological
examination of passaged tumour indicates that initial infiltration occurs in the spleen, lymph nodes, Peyer's
patches and liver, while in the terminal phase the bone marrow, gonads and occasionally the central nervous
system become involved. The terminal spread is coincidental with the leukaemic phase in the tumour.
The tumour cells show typical B cell characteristics in vitro. These include surface immunoglobulin (Ig) of
P,K isotype, surface Ia, Thy-I negativity and an increased uptake of tritiated thymidine following incubation
with lipopolysaccharide. A31 cells secrete low levels of IgM into the tissue culture fluid. Short-term culture
produced only 100 ngIgM per 107 cells over 8h and no tumour-associated monoclonal band could be
detected in the serum of tumour-bearing mice.
Chromosomal karyotypes of A31 cells gave model numbers 2n=40 normal, and 2n=41, with partial
trisomy of chromosome 2, and trisomy of 17. There was loss of a chromosome 6 and the Y chromosome,
together with the translocation of part of an 11 to one of the two unidentified marker chromosomes. The
responses of lymphoma-bearing mice to therapeutic levels of cyclophosphamide and vincristine sulphate and
also to whole body X-radiation are illustrated. This tumour may help in unravelling the complex biology of B
cell lymphoma and because of its low level of Ig secretion, be of particular value in experimental
immunotherapy.
Slow but steady progress is being made in the treat-
ment of lymphoid malignancy, particularly B cell
leukaemia, and to a lesser extent non-Hodgkin's
lymphoma. One aspect ofthis field that has attracted
particular attention in the last few years has been
the use of anti-idiotype antibody in the treatment
of B cell tumours. This interest was in part initiated
by a report from Miller et al. (1982) of significant
regression induced in a patient with advanced B cell
lymphoma using a mouse monoclonal anti-idiotype
antibody. Although attempts to repeat this finding
with other patients have so far met with only
limited success the idea of using an anti-idiotype
antibody in the treatment of lymphoma remains
attractive (Lowder et al., 1985; Stevenson &
Glennie, 1985). If the antibody is ineffective on its
own, it may be that it can be endowed with
cytotoxicity by being coupled to toxins, drugs or
radionuclides. Investigations into therapy with anti-
idiotype antibody used alone have highlighted a
number of problems. For example, not all
lymphomas are mono-idiotypic and therefore a
cocktail of anti-idiotype antibodies may be neces-
sary (Sklar et al., 1984); antigenic modulation
provides temporary protection for the tumour cells
(Gordon & Stevenson, 1981) and complexing of the
anti-idiotype with secreted circulating antibody can
provide a further barrier to effective therapy
(Stevenson et al., 1980a). Our investigation of the B
cell lymphoma A31 indicates that it is probably
monoclonal and exhibits only a low level of cir-
culating idiotype which removes two of the
obstacles to experimental immunotherapy of mice
bearing this tumour.
The characteristics of A31 illustrated in the
following report, which includes histopathology,
immunochemistry, cytogenetics and responses to
drugs and radiation, suggest that this tumour may
prove valuable in the development of techniques for
the effective therapy for B cell lymphoma in man.
A31 may also help to increase our understanding of
the biology of the normal B lymphocyte.
Materials and methods
Experimental animals
The mice used were inhouse-bred male and female
CBA/H.
B cell lymphoblastic Iymphoma A31
The tumour arose in 1971 in one of a group of
CBA/H female mice injected i.p. 19 months
previously with 240 kBq 90Sr. As well as a spindle
cell tumour of the spine (probably originating in
bone) there was at autopsy an anterior mediastinal
tumour mass and an enlarged 'fleshy' spleen. The
cells in the thoracic mass (which could have arisen
from a tracheobronchial lymph node or the
thymus) were malignant lymphocytes, as were the
cells infiltrating the spleen. Tumour cells from the
mediastinal mass were implanted into CBA/H mice
and repeatedly passaged using cells from enlarged
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spleens (1971-1984; .100 passages). In 1984
cloning was attempted by i.v. injection of a
nominal one cell per mouse into a group of 10
animals. This was repeated on the next passage
using the spleen from one of the longest surviving
mice. The resultant infiltrated spleens were stored in
liquid nitrogen and characterisation commenced.
The data in this paper relate to passages - 105-
115; and the cells, held in the Radiobiology Unit,
are available to other laboratories. Tumour 'takes'
can be obtained with a nominal single cell i.v. and
10 cells i.p. or s.c. The s.c. inoculation does not
produce a local mass but the draining lymph node
becomes larger than the contralateral node.
In this paper we are, for the sake of brevity,
calling A31 a lymphoma; however, the more
cumbersome terms lymphoma/leukaemia, or
lymphoblastic lymphoma with terminal leukaemia,
would be more accurate as they emphasize that in
the terminal phase of the disease there are
significant numbers of circulating tumour cells.
Pathology of A31 lymphoma
Gross pathological examination was carried out on
mice at - 20 days and - 30 days following the
injection of cell numbers varying from 102 to 105;
all suspended in PBS and injected i.p., s.c. (dorsum
of hind foot) or i.v. Following the autopsy in some
mice all the major organs, lymph -nodes and
sternum were fixed in either formalin or Bouin's
fluid, sectioned and stained with Mayer's
haematoxylin and eosin. In other mice the major
organs were frozen and cryostat sections cut for
indirect staining using our own sheep anti-idiotype,
and horse-radish peroxidase-conjugated rabbit anti-
sheep second antibody (Dako Ltd., High Wycombe,
Bucks). For cytological examination of A31
imprints were made from the cut surface of the
grossly enlarged spleens from terminally affected
mice. The imprints were air-dried, methanol fixed
and stained with Giemsa, methyl green-pyronin, oil
red 0 or Sudan black.
Ultrathin sections of an A31 cell pellet were
prepared for electron microscopy. The pellets were
obtained by teasing apart the enlarged spleens of
terminal mice, washing the cells in PBS, centri-
fuging gently and fixing the pellet in 2.5% glutar-
aldehyde in 0.1 N sodium cacodylate buffer,
postfixing in Millonig's buffered osmium tetroxide
(1% OS04) and embedding in Spurr's resin.
Blood for peripheral cell counts was taken on
days 7, 14, 21 and 28 following the i.v. injection of
5 mice with 103 A31 cells. A count was made of
total lymphocytes, both normal and malignant.
The results from this Pathology section are based
on examination of tissues and cells from 90 mice.
Immunogenicity ofA31
Twenty male CBA/H mice were inoculated s.c. with
A31 cells sterilised by a 2min exposure to 60Co y-
rays (total dose 150Gy). The mice were given 2
inoculations, each of 106 sterilized cells in 0.1ml
PBS into opposite flanks separated in time by 2
weeks. Four weeks after the second immunising
injection the animals were separated into 2 groups
of 10 mice each to be injected s.c. with viable A31
cells. By diluting from 106 cells, suspensions for i.v.
injection were prepared of a nominal single cell for
one group and 100 cells for the second group. Each
of the 2 groups had a companion nonimmunised
control group of 10 mice also receiving either 1 or
100 viable cells. The 40 animals were observed until
they were killed either because they were moribund,
or the study completion date of day 100 after the
injection ofviable cells was reached.
Immunochemical investigations
Cell suspensions (A31, BCL1, L2C). A31 cells
were harvested from the peripheral blood, bone
marrow or spleens of CBA/H mice bearing the
lymphoma. The details of tumour cell preparation
are given separately for each of the procedures.
BCL1 lymphoma cells for immunofluorescence
staining were obtained from a line provided by Dr.
S. Slavin (Knapp et al., 1979). It was maintained by
passage in the syngeneic host, BALB/c mice. Cells
from the spleens of near-terminal animals were
disaggregated through a fine gauze in Dulbecco's
MEM (Gibco, Paisley) and then isolated by
gradient centrifugation on Ficoll-Hypaque followed
by washing as described previously (Stevenson et
al., 1980b).
L2C lymphocytic leukaemia cells for immuno-
fluorescence staining (Nadel, 1977) were maintained
by continuous passage in strain 2 guinea pigs.
Blood was drawn from terminal animals by cardiac
puncture into 0.2 vol of 120mM sodium citrate, pH
7.4. The cells were separated and washed as
previously described (Gordon & Anderson, 1980).
Immunofluorescence staining for heavy chain, light
chain and Thy 1.2 Examination of surface fluor-
escence ofA31 lymphoma cells was carried out using
the fluorescence-activated cell sorter (FACS III,
Becton-Dickenson Electronics, Mt. View, California).
Disaggregated and washed splenic, or peripheral
blood cells (2 x 10 ml-1) from mice in the
terminal stages of the A31 lymphoma were treated
for 30min at 4°C with the following anti-mouse
antibodies (predetermined working concentrations):
fluorescent (FITC)-sheep anti-immunoglobulin yMURINE B CELL LYMPHOMA 809
(Serotec Ltd., Bicester, Oxon.); FITC-goat anti-6;
FITC-goat anti-p; FITC-sheep anti-. (Nordic
Laboratories Ltd., Maidenhead, Berks.); or
monoclonal antibodies that react with the
immunoglobulin K chain (HB58: ATCC, Rockville,
Maryland), Ta (courtesy Dr. A. Oliver, University
of Edinburgh) or Thy 1.2 (30H 12.1 - Dr.
Herzenberg, Stanford University, California).
Following washing, cells were examined by flow
cytometry, or in the case of monoclonal reagents
exposed to FITC sheep antibody reactive with the
Fc region of the monoclonal IgG, diluted appro-
priately (Serotec). Control samples of cells were
treated with an appropriate concentration of FITC-
sheep normal IgG or mouse normal IgG followed
by the fluorescent antibody.
Secretion profile Disaggregated spleen cells from
terminal A31-bearing mice were suspended in
supplemented Dulbecco's MEM medium at
1.4 x 107 ml 1, at 37°C with gentle swirling
(Stevenson et al., 1980b). Samples were taken at
intervals, cooled to 0°C and cells removed by
centrifugation (200g). The estimation of 1gM in the
culture fluid was carried out by enzyme-linked
immunosorbent assay (ELISA) (Engvall &
Perlmann, 1972) using sheep anti-mouse IgM
(Serotec) at 1 pgml-1 on the plate to bind IgM and
an appropriate dilution of horse-radish peroxidase-
labelled goat anti-mouse p (Nordic Laboratories
Ltd.). Purified IgM (courtesy Mr. N. Richardson,
Babraham, Cambridge) from the mouse plasma-
cytoma TEPC 183 was used as a standard in all
calibrations.
FcR and CR receptors Receptors for the Fc region
of IgG (FcR) and for the third component of
complement (CR) were determined by a modifi-
cation of the rosetting procedure described by
Knapp et al. (1979). Briefly, fresh sheep red blood
cells (SRBC) were washed in PBS, exposed to a
subagglutinating concentration of rabbit anti-SRBC
(courtesy of Dr. A. Wild, Department of Zoology,
University of Southampton) (7% SRBC v/v) for
120min at 37°C, and then washed three times in
PBS. The detection of FcR used an IgG anti-SRBC
to sensitise the SRBC (IgG-EA), while the test for
CR required an IgM anti-SRBC (IgM-EA).
Coating the IgM-EA with complement (IgM-EAC)
without causing cell lysis was achieved by exposing
to normal mouse serum, diluted 1/4 in Dulbecco's
MEM, for 30min at 30°C before washing in PBS.
Rosettes were generated by pelleting (200g) washed
spleen lymphocytes from tumour-bearing animals
(5 x 106 ml-1) with an equal volume of the
sensitised SRBC (0.7% v/v) (IgG-EA or IgM-EAC).
Cell pellets were resuspended by gentle agitation
and scored for rosette formation (mononuclear cell
binding at least 3 SRBC) in the presence of one
drop of acridine orange (0.05%) using a Leitz
Dialux 20 fluorescence microscope. At least 200
mononuclear cells were scored for each sample.
Measurement of [6-_3I] thymidine uptake following
LPS stimulation ofA31
To determine the effect of bacterial lipopolysac-
charide (LPS) on A31 cells, the lymphoma-
infiltrated spleens were taken from 3 female CBA/H
mice that had been inoculated with 105 tumour
cells i.p. 28 days previously, Spleens from age-
matched normal control mice were used for
comparison. The thymidine uptake assay was
similar to that described by Roess et al. (1983).
Briefly, LPS from E. coli 0127:B8 (Difco, Detroit,
Michigan) was prepared in a doubling dilution
series (0.1 ml/well) to cover the range 500upgml-1
down to 3.9pgml -1. Spleen cell suspensions
(0.1 ml) were added to the LPS in 96 well culture
plates (105 cells/well). For all procedures the culture
medium was RPMI 1640 supplemented with
pyruvate (1 mmol 1 1), glutamine (2mmol 1),
NaHCO3 (25mmol1 1), penicillin (100IUml 1),
streptomycin (100pgml 1), 2-mercaptoethanol
(0.05mmol -1) and heat inactivated foetal bovine
serum (5%). The preparations were incubated at
37°C under 5% CO2 in air and after 44h 18.5kBq
[6-3H] thymidine ([3H]-TdR Sp.Act. 0.96
TBqmmol- 1, Amersham International plc,
Amersham, Bucks) was added to each well.
Thymidine incorporation was terminated 4h later
by the addition of aminopterin (to a concentration
of 0.18mg -1) and the cells harvested onto glass
fibre filter papers. The activity retained in the DNA
on the filters was measured by liquid scintillation
counting.
Cytogenetic preparations
The cells for chromosome analysis were taken from
mice killed 9-30 days after i.p. injection of 103
tumour cells (Table I). Chromosome preparations
were made directly from the femoral bone marrow
and the spleen, using a modification of Ford's
technique (Ford, 1966). Briefly, the cells were sus-
pended in RPMI 1640 culture medium (Flow Labs.,
Irvine, Scotland) with 5% foetal bovine serum and
subjected to a short exposure of colcemid (Ciba,
Horsham, Surrey - 0.05pgml-1 for 10min at
37°C). They were then subjected to hypotonic treat-
ment in 0.5% (w/v) KCI for 15min, followed by
fixation in 3 parts methanol to 1 part glacial acetic
acid. The cells were resuspended and air dried onto
dry slides. The staining was by Brevans mountant
(Breckon, 1984) or, after ageing 3-10 days at room810 L.M. COBB et al.
temperature, the slides were stained with
acetic:saline:Giemsa (ASG)/trypsin and G banded
by a modification of the method described by
Gallimore & Richardson (1973). From each sample
5-8 ASG/trypsin karyotypes were prepared from
enlarged photographs taken on Kodak Technical
Pan 2415 film and a further 10-30 metaphases were
analysed directly under the microscope. All
grouping and numbering followed the system
recommended by the Committee on Standardised
Genetic Nomenclature for Mice (C.S.G.N.M, 1972).
Chromosome counts (metaphase) to establish clonal
distribution are given in Table I.
Short-term (48h) cultures were established from
mice killed 9-30 days after 103 A31 i.p. using
cardiac blood and spleen cell suspensions in RPMI
1640 culture medium with 18% heat inactivated
foetal bovine serum with 300jugml-1 of L-
glutamine and stimulated either with concanavalin
A (Con A - Pharmacia, Milton Keynes, Bucks;
10jgml-') for the analysis of predominantly T
lymphocytes, or poke-weed mitogen (PWM -
Gibco, Paisley, Scotland; 0.05ml of reconstituted
PWM per 5ml of culture medium) for the
stimulation of predominantly B lymphocytes
(Janossy & Greaves, 1971). The slide preparation
was similar to that used for the direct tissue
examination except that the colcemid concentration
was 0.01 gmlP-1 for 1-2h.
Treatment by drugs and X-radiation
The response of mice bearing A31 lymphoma was
observed following treatment with cyclophos-
phamide (Farmitalia Carlo Erba Ltd., Barnet,
Herts) and vincristine sulphate (Sigma, Poole,
Dorset). Both drugs were injected at the maximum
tolerated dose. The maximum tolerated dose is
defined as that dose which, although not lethal,
causes a significant depression in one or more
bodily functions and also commonly results in the
animal losing weight. The cyclophosphamide was
injected on days 15, 21 and 28 following 105 A31
s.c. (i.p. 0.025mgg-1 body wt. twice daily on each
day) and vincristine sulphate was given on the same
basis except that the dose was 0.5mgg-1 body wt.
and was given only once on each day, and i.p.
The X-irradiation was given at a potentially lethal
dose and the animals subsequently rescued by the
i.v. injection 24h later of 106 viable bone marrow
cells from a normal syngeneic donor. The X-rays
were generated from a single source of 250kV,
HVL 1.1mm Cu giving a field uniform to +3%.
The dose rate was 58 mGymin 1 and the mice were
irradiated total body for 2h 40min (9.5Gy). The
total body irradiation (TBI) was given to mice
15days following 105 A31 s.c.
The response of the mice to drugs and to X-ray
treatment was measured as extension of life span
compared with untreated control mice inoculated
with a similar number of A31 cells. See Table II for
details of controls and numbers of animals per
group.
Results
Gross and microscopic pathology
The mice became terminally ill 27-52 days after the
injection of 102-105 A31 cells by any of the 3
routes of administration; at this time there was
generalised piloerection and the abdomen was
markedly distended. The animals would die within
48 h of these signs. At autopsy the spleen was
grossly enlarged, -20 times normal size and the
liver, which was moderately enlarged, displayed a
uniform pale mottling. Lymph nodes and Peyer's
patches were approximately twice the normal size
but no other tissues appeared abnormal. The only
difference in gross pathology produced by using
different routes of administration was that with the
i.p. route the mesenteric nodes were larger than
following i.v. or s.c. injection and with s.c. injection
into the hind foot the ipsilateral popliteal and flank
nodes were larger than the contralateral ones.
The histopathology of early infiltration was
examined in mice killed 20 days after the
injection of A31 cells. At this time the only gross
pathological change was a minimally enlarged
spleen. Histopathology (routine paraffin sections
and anti-idiotype preparations) of the spleen,
Peyer's patches and lymph nodes showed tumour
infiltration of the normal B cell domains. The
malignant cells occupied approximately 20% of
these organs/tissues. The only other organ showing
infiltration was the liver where small clusters of
A31 cells were observed either beneath the
endothelium of the centrilobular vein or around the
branch of the hepatic artery and adjacent bile duct
in the portal areas.
The histopathology at -30 days, as would be
expected, showed much more extensive infiltration.
By this time the tumour cells had obliterated the
splenic architecture leaving only small aggregations
of normal lymphocytes around the central
arterioles. The lymph nodes and Peyer's patches
were also packed with malignant lymphocytes. In
some nodes the malignant cells were seen extending
into the extra-capsular site (Figure 1). Scattered in
between the malignant lymphocytes were large
macrophages giving the tissue a 'starry sky'
appearance reminiscent of Burkitt's lymphoma. The
liver was heavily infiltrated throughout and
moderate infiltration was commonly observed in
bone marrow, testis/ovary, lung (peribronchial and
perivascular spaces) and adrenal gland. OnlyMURINE B CELL LYMPHOMA 811
Table I A31 B cell lymphoma - chromosome clonal presentation.
Day post
inocula- Metaphases examined by Metaphases examinedfrom short term
tion direct cytology cultures, 48h
Chromosome Chromosome
counts <39 39 40 41 42 4n counts <39 39 40 41 42 4n
9 BM 3 83 10 4 Blood Con A 100
Spleen 9 46 41 3 1 Blood PWM 100
Spleen Con A 1 99
Spleen PWM 2 94 4
15 BM 2 3 85 10 Blood NILa 2 96 0 2
Spleen 1 2 60 33 4 Blood Con A 6 89 4 1
Blood PWM 1 4 71 22 2
Spleen Con A 2 87 10 1
Spleen PWM 2 3 48 43 4
20 BM 1 0 93 6 Blood Con A 3 83 14
Spleen 2 2 19 77 Blood PWM 4 15 80 1
Spleen Con A 2 3 74 19 2
Spleen PWM 1 11 85 3
26 BM 1 2 82 15 Not sampled
Spleen 4 3 32 61
30 BM 2 54 42 2 Blood Con A 0 96 4
Spleen 2 66 29 3 Blood PWM 0 90 10
Spleen Con A 0 2 94 4
Spleen PWM 1 2 80 17
Numbers indicate number of metaphases scored per sample of 100. 2 samples/mice - per point - mean values - +s.e. +0.55 to
+1.24; BM=Bone marrow; Con A=Concanavalin A, T cell stimulant; PWM=Poke-weed mitogen, B cell stimulant; 'NIL=no
stimulants added.
Table II The prolongation of survival in mice bearing
established A31 lymphoma following treatment with
VCR, CYC and TBI X-rays.
Experiment A31 No. of Time to death
no. inoculum mice Treatment in days median
M1O 105 s.c. 10 VCR 57
M1O 105 s.c. 10 Control 36
Mll 105s.C. 10 CYC 72
M11 105 s.c. 10 TBI 50
M1l 105 s.c. 10 Control 35
CYC =Cylophosphamide i.p. 0.025mgg- 1 twice daily,
days 15, 21 and 28 post-implant; VCR=Vincristine sul-
phate i.p. 0.5mgg-1 daily, days 15, 21 and 28 post-
implant; TBI=Total body X-irradiation. 9.5 Gy X-rays
day 15 post-implant; The controls received no injection of
drugs or solvent.
Figure 1 Lymph node heavily infiltrated with A31
lymphoblastic lymphoma cells. Normal lymphocytes
constitute -10% of the cell population. A slim wedge
of these is seen outside the capsule (asterisk). The
'starry sky' appearance is produced by scattered
macrophages (arrows). The lymph node capsule and
the subcapsular sinus are indicated by arrow heads.
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occasionally was the tumour seen in the thymus,
kidney or brain. In the occasional instances of
brain involvement meningeal infiltration was seen
to arise by extension from the heavily involved
cranial bone marrow.
Cytology, histochemistry and electron microscopy
The Giemsa stained imprints of the spleens of
terminal mice showed the tumour cells to be large
(- 15 pm diameter) with pale blue cytoplasm and in
some cells there were 1-5 large clear cytoplasmic
vacuoles. The cells resembled those of lympho-
blastic lymphoma in man. The nuclear chromatin
was present as aggregates, usually attached to the
nuclear membrane. There were 2 or 3 prominent
nucleoli. A common feature was the clustering of
tumour cells around large macrophages. Methyl
green-pyronin produced a diffuse pink stain
throughout the cytoplasm indicating small amounts
of RNA. Attempts to stain the cytoplasmic
vacuoles for lipid using oil red 0 or Sudan black
were unsuccessful.
Transmission electron microscopy of a washed
spleen cell pellet showed lymphoblastic cells with
occasional small surface villi and a cytoplasm with
scattered mitochondria, a small amount of rough
endoplasmic reticulum and numerous ribosomes.
The chromatin appeared as dense aggregates close
to the nuclear membrane and occasionally
extending towards the centre. These extensions
frequently encompassed one of the large nucleoli.
Peripheral blood counts
Following the i.v. injection of 103 A31 cells the
mean (of 5 mice) total lymphocyte counts (normal
and malignant) in peripheral blood rose through
days 7, 14, 21 and 28 to 6x103, 6x103, 2x104
and 2x lO cells pPl- respectively. The normal
lymphocyte count of CBA/H mice is 5-9 x 103 cells
,p1
Immunogenicity ofA31
No animals from the 2 groups of 10 mice
challenged with a nominal single A31 cell on this
occasion developed lymphoma. In the 2 groups of
mice, 10 immunised and 10 non-immunised, chal-
lenged with a nominal 100 A31 cells the first mouse
succumbed to the tumour at 37 days in the
immunised group and 39 days in the non-
immunised control group. The median survival time
for both groups of mice was 49 days. This indicated
clearly that A31 was not immunogenic by the
technique used in the present study.
Immunochemistry - B cell markers expressed by A31
lymphoma
Surface immunofluorescence studies on A31
lymphoma cells showed clearly that this was a
tumour of B cell lineage, which expressed surface
IgM with a K light chain. Antibodies specific for
the p, 6, y, A, and K Ig chains could detect only the
p heavy chain and K light chain on A31 cells
derived from spleen (Figure 2) or peripheral blood
(data not shown) of tumour-bearing animals. These
cells also expressed class II histocompatibility
molecules (Ta), but not the T cell marker Thy 1.2
which is present on CBA/H mouse T lymphocytes
(Figure 2).
In addition to surface Ig we have also looked for
secretion of IgM by A31 cells during short-term
culture in vitro (Figure 3). IgM is released, probably
as a 19S molecule (Stevenson et al., 1980b), but at
levels which are consistent with a low secreting
tumour (Stevenson et al., 1980a). Such an
interpretation is supported by the fact that we have
been unable to detect a tumour-associated mono-
clonal band in the serum of A31-bearing mice, even
when using sensitive techniques such as isoelectric
focusing with immunoprecipitation (data not
shown).
Tumour cells from the murine lymphoma BCL1
(Knapp et al., 1979), and the guinea pig leukaemia
L2C (Shevach et al., 1972), were tested alongside
A31 cells for the presence of FcR and CR by
rosetting with sensitised SRBC. Table III shows
that while the BCL1 and L2C tumours were
positive for FcR and CR respectively, the A31
lymphoma was negative for both. The presence of
these receptors on BCL1 and L2C has been
described previously (Shevach et al., 1972; Knapp
et al., 1979) and suggests that their absence from
A31 cells is not a result of detection difficulties.
However, it is known that CR can show low
binding for sensitised SRBC, making them difficult
to detect without a more sensitive technique such as
immunofluorescence with a monoclonal anti-CR
antibody (Dr. D. Jones, University of
Southampton, personal communication).
Table III FcR and CR expression on A31 lymphoma cells.
% rosetteforming cells with sensitised
and unsensitised SRBC8
Tumour cells SRBC IgG-EA IgM-EA IgM-EAC
L2C 0 0 0 61
BCL1 0 86 0 4
A31 1 2 2 5
aTest performed on at least 2 animals for each tumour.MURINE B CELL LYMPHOMA 813
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Figure 2 Surface markers detectable on A31 lymphoma cells as shown by the fluorescence-activated cell
sorter (FACS III). Cells at 2 x 107 ml-1 were exposed to: (a) control FITC-sheep normal IgG: (b) monoclonal
anti-Ia; (c) FITC-goat anti-y; (d) monoclonal anti-k chain (HB 58). After washing, bound mouse antibody
was detected by fluorescent anti-mouse Ig where necessary, and cells analysed by FACS III. Negative
distribution profiles (a) were obtained with antibodies that reacted with Ig-5, y and A chains, and the T-cell
marker Thy 1.2. Fluorescence gain= 2.2.
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Figure 3 The production of extracellular IgM by A31
lymphoma cells in culture. The cells were suspended in
supplemented Dulbecco's MEM at 1.4 x 107 ml- 1 and
swirled gently at 370C. At intervals 2ml aliquots were
removed, chilled, and assayed for IgM after removal
of the cells.
The effects ofLPS on A31 in culture
Figure 4 illustrates the striking effect of LPS on
[3H]-TdR incorporation into A31 and into normal
spleen cells, and Table IV summarises the statistical
evaluation. All concentrations of LPS stimulated
[3H]-TdR incorporation into normal cells, although
a reduction in cpm was noted at 500jugml-1
compared with 250 gml-1. For the lymphoma
cells LPS was clearly enhancing [3H]-TdR incorpor-
ation above the basal level up to a concentration of
125 Mgml 1 although this was much reduced at
250pgml-1 LPS and at 500jugml -1 was not
significantly different from zero (0 pgml-1 LPS).
There was obviously a threshold above which LPS
was no longer stimulatory to the lymphoma.
In making a statistical comparison the data were
logarithmically transformed in an attempt to
overcome the fact that the variances were (a)
greater in groups with high mean cpm than in
groups with low mean cpm, and (b) the variances
were on average greater for normal spleen cells
than for A31 cells. A comparison was then made
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Figure 4 The effect of lipopolysaccharide (LPS) on
3H thymidine incorporation into A31 lymphoma (0)
and normal spleen (0) cells in vitro. Each point
represents the mean with standard error for cells taken
from the spleens of 3 mice. Very small standard errors
could not be represented for some of the points.
Table IV Statistical evaluation of the differences in count
rates ofcells cultured in the presence of LPS.
Stimulation above zero Stimulation above
LPS in LPS normal spleen
culture
medium Normal spleen A31 cells A31 cells
igml1- p p p
0 - 0.042*
3.9 0.0034** small*** 0.046*
7.8 0.0021** small*** 0.048*
15.6 0.0012** small*** 0.066
31.3 0.0013** small*** 0.047*
62.5 0.0015** small*** 0.036*
125 0.0010** small*** 0.046*
250 0.0013** 0.0028** 0.12
500 0.010* 1.0 0.0003***
One-tailed probability (P) values were calculated for
comparing normal spleen cells and for comparing A31
cells with unstimulated cells (18 df). Details of the com-
parison between the two cell types is given in the text.
Significance levels were taken as P<0.05 (*), P<0.01 (**)
and P<0.001 (***)
using the Aspin-Welch t test, and it was shown
that, with one exception (15.6pgml-1), all concen-
trations of LPS between 0 and 125 4gml-1 gave
significantly greater [3H]-TdR incorporation
(P<0.05) into A31 cells than into normal spleen
cells. At 250pgml-1 the difference was not signi-
ficant and at 500jgml- 1 significantly less [3H]-
TdR was incorporated into A31 cells than into
normal cells.
Chromosome analysis
The karyotype results are summarised in Table I
and Figure 5. They show that with specific
lymphocyte mitogens in the short-term cultures the
clone cells carrying the neoplastic chromosome
markers (2n=41) were increased in frequency in
PWM cultures but not with the mitogen Con A
(Table I). This indicates that the cells which
karyotype with the neoplastic chromosome markers
are predominantly of B cell origin. In this section
on cytogenetics the term clone is used for a
population of cells which is assumed to have arisen
from one cell and the individual cells have an
identical karyotype except for minor deviations.
Elsewhere in the paper a clone refers to a
population of cells probably originating from one
cell, irrespective of any possible differences in
karyotype.
The occurrence and percentage of clone cells
present altered over time on direct examination. In
the bone marrow the percentage of clone cells was
maintained at approximately the 10% level until
the terminal state (30 days) when it rose to 42%. In
the spleen the increase was from 35% at 9 days to
a peak of 77% at 20 days with a subsequent decline
to 30% at 30 days. In the in vitro cultured cells the
percentage of clone cells was zero at 9 days for
both spleen and blood indicating that in the spleen
and blood detectable infiltration of malignant cells
had not occurred at this time. The peak of
malignant cells in the cultured spleen was 85%
which again was at day 20 post-inoculation, as also
was the peak for blood at 80%.
Drug and X-ray treatment ofA31
The 2 groups of control non-treatment mice
inoculated with 105 A31 s.c. died with median
survival times of 35 and 36 days (Table II).
Following treatment with vincristine,
cyclophosphamide and TBI the median survival
time was extended to 57, 72 and 50 days
respectively.
Discussion
In the past decade the results of the treatment of
the aggressive form of B cell lymphoma have
shown that there is slow but steady progress. The
advances have come mainly from the introduction
of improved drug regimens. The possibility that
anti-idiotype antibodies might also have a place in
the treatment of B cell lymphoma/leukaemia
(Hamblin et al., 1980) was given encouragement in
1982 by a report by Miller et al. of a complete
remission in a patient treated with a mouse anti-
idiotype monoclonal antibody. It is disappointing
that a similar response has not yet been observed in
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Figure 5 Karyotype and clone data of A31 tumour. Example of an ASG banded karyotype of clone A from
a PWM stimulated spleen cell, 48h culture.
CLONE 2n =39-y - 26 of the 42 metaphases karyotyped with 2n=39 had the Y chromosome missing. The
rest had a single chromosome loss which was not repetitive, and therefore did not constitute clones, and could
be metaphases broken at the preparative stage.
2n=40 Df (2;2) - 6% of the 2n=40 metaphases had a deletion of chromosome 2. (df: 2:2) The rest had an
apparently normal karyotype.
2n =41 Clone A - the predominant clone at 89% of the 2n=41 metaphases analysed.
Clone A Ts (2 with 2 Df 2:2) - Chromosome 2, trisomic with two chromosomes deleted at E.I. to F.3. M6 -
Chromosome 6 - monosomy.
T (11; 4: MAR 1: 3) - Chromosome 11 - translocation of a segment, 4 to marker chromosome no. 1 at
region 3. TS17 - Trisomy 17. -Y - Loss of chromosome Y.
MAR I/T (11: 4: MAR 1; 3) - Translocation of region 4 of chromosome 11 to region 3 of marker 1. (Rest of
marker not identified.) Mar. 2 - Marker 2 not identified.
Clone B 2n=41 TS 5 - Clone B 2n=41, trisomic for chromosome 5, Y present 11% ofcells analysed.
2n=42 - 2% of the population analysed. TS; 5, TS; 13 - Trisomic for chromosome 5 and 13. Y present.
Plus a small percentage of cells with abnormal chromosomes and aneuploidy (3%) which did not exist at a
clonal level; i.e. minimum of three metaphases with the same karyotype.
No variations in clonal karyotype analysis was observed between the metaphases examined by the direct
technique and by short term culture.
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subsequent patients by these (Meeker et al., 1985)
or other workers (Rankin et al., 1985). A number
of research groups are examining closely the part
that anti-idiotype antibodies may play in the
therapy of lymphoma used alone (Lowder et al.,
1985), with attached drugs and toxins (Gilliland et
al., 1980; Embleton et al., 1983), or carrying cell-
sterilising amounts of radionuclides (Larsen et al.,
1983). In B cell lymphoma/leukaemia a major
problem can arise in some patients from large
quantities of circulating idiotype which can
effectively block the entry of the therapeutic
antibody into the tumour infiltrated tissues (Meeker
et al., 1985). It would seem therefore that successful
treatment is more likely to be attained in patients
with minimal levels of circulating idiotype.
The present tumour model, A31 in CBA/H mice,
provides a close parallel to aggressive B cell
lymphoma in man. As in man the A31 cells infil-
trate aggressively the B cell domains of the
lymphoreticular system and at a late stage the
gonads and, less frequently, the central nervous
system (CNS). The infrequency of terminal
involvement of the CNS in the mouse might appear
to be different from the situation in man where
CNS involvement is a common problem. However,
in man the CNS is usually only a clinical problem
as a site of relapse following treatment. Overt CNS
involvement in non-Hodgkin's lymphoma occurs in
less than 10% of patients at diagnosis (Levitt et al.,
1980), and in acute lymphoid leukaemia CNS
involvement is observed in less than 5% of children
at diagnosis, and is rarely symptomatic (Bleyer,
1983).
We have included in this presentation the results
of the response to drugs and X-radiation shown by
mice with established B cell lymphoblastic
lymphoma. There is clear response to a number of
the drugs used in the therapy of this disease in man
and also clear response to TBI, which is only rarely
used in man for this disease.
The present work has shown that the A31
lymphoma is derived from the B cell lineage,
expressing surface IgM with a K light chain and the
Ia antigen. There was no evidence from immuno-
fluorescence studies of the Thy 1.2. antigen found
on T cells, or surface Ig of other isotypes. In
particular we found no IgD which has been
reported on other murine B cell lymphomas
(Knapp et al., 1979) and on the majority of human
B cell leukaemias and lymphomas (Fu et al., 1975).
The A31 lymphoma was also negative for surface
FcR and CR using the appropriately sensitised
SRBC - although their presence on two other
animal B cell tumours, BCL1 (FcR) and L2C (CR),
was confirmed in the present study (Shevach et al.,
1972; Knapp et al., 1979). The absence of such
receptors from the surface of A31 cells compared
with BCL1 and L2C, is consistent with a tumour
arrested at a different stage of B cell maturation
(Rosenberg & Parish, 1977), or their loss during the
process of tumour de-differentiation.
The secretion profile of IgM from A31 cells into
the extracellular fluid was assessed during short-
term culture in vitro. Immunoglobulin M was
released over a 20h period, but at levels which were
consistent with a low secretor of Ig (Stevenson et
al., 1980a). Previous experience with B cell
neoplasms has shown that this material represents
small amounts of pentameric IgM released via a
secretory pathway, rather than Ig turned over on
the cell surface. Any contribution from the cell
surface is most likely to occur as vesicle-bound Ig
shed from the cells during culture (Stevenson et al.,
1980a). The absence of a detectable monoclonal
band in the serum of tumour-bearing animals, even
using sensitive techniques such as isoelectric
focusing with immunoprecipitation, is also
consistent with a low level of secretion.
A31 is potentially an eminently suitable model
for immunotherapy investigations using anti-
idiotype antibodies. Its abundant surface IgM with
only minimal IgM secretion should ensure an
almost unrestricted access of antibody to the
tumour cells. Similar tumours described for the
mouse, such as the BC11 of BALB/c, have often
secreted significant levels of idiotypic IgM which
provides a barrier to any therapeutic antibody (Tutt
et al., 1985). Production of anti-idiotype antibody
for the A31 will probably require the isolation of
the idiotypic IgM: in the present work idiotypic
determinants associated with the whole tumour cell
did not prove sufficiently immunogenic to generate
a protective immune response. A number of
techniques exist to provide this material (Stevenson
& Glennie, 1985), but probably the most straight
forward will be the production of a hybridoma
between the A31 and a non-secreting mouse
myeloma such as NS-1, which will secrete the
tumour IgM. Armed with the 'rescued' IgM it
becomes feasible to hyperimmunise animals for the
production of both xenogeneic and syngeneic
monoclonal anti-idiotype antibodies (Maloney et
al., 1985).
The cytogenetic studies showed that a character-
istic of the dominant clone in the A31 tumour was
deletion of an interstitial region of chromosome 2.
Hayata et al. (1983) have reported deletion and loss
of a segment of chromosome 2 in 44 of 52 cases of
X-ray induced murine myeloid leukaemia. This
change was seen irrespective of differences in mouse
strain, sex and stage of tumour differentiation. This
chromosome abnormality however was not
observed in 30 cases of murine lymphoid leukaemiaMURINE B CELL LYMPHOMA 817
(Hayata, unpublished data) nor in 9 cases of non-
myeloid leukaemia examined in this laboratory. As
far as we are aware this is the first observation of a
chromosome 2 rearrangement in a non-myeloid
leukaemia. The partial trisomy of chromosome 2 in
A31 is a new observation as is the loss of
chromosome 6, unless a part is translocated to
either marker 1 or 2. Translocation of part of
chromosome 11 is an uncommon event as is
trisomy for 17. Variation in the presence or absence
of the Y chromosome together with duplication is a
common event in human and mouse myeloid
leukaemia.
In summary, we are reporting the characteristics
of a new murine B cell lymphoma which show that
it is similar in many ways to aggressive B cell
lymphoma in man. This would make it a useful
model for the therapy of this disease and in
addition it may be of value in expanding our
knowledge of the biology of both normal and
malignant B lymphocytes of mice and men.
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